Difference between revisions of "Sacituzumab govitecan (Trodelvy)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 2: Line 2:
 
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=736415 NCI Drug Dictionary]: An antibody-drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis.  
 
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=736415 NCI Drug Dictionary]: An antibody-drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis.  
  
−
==Preliminary data==
+
==Diseases for which it is used==
−
===[[Breast_cancer,_triple_negative|TNBC]]===
+
*[[Breast_cancer,_triple_negative|TNBC]]
−
* Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2017 Jul 1;35(19):2141-2148. Epub 2017 Mar 14. [https://doi.org/10.1200/JCO.2016.70.8297 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28291390 PubMed]
 
−
 
 
−
===[[Non-small cell lung cancer]]===
 
−
* Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017 Aug 20;35(24):2790-2797. Epub 2017 May 26. [https://doi.org/10.1200/JCO.2016.72.1894 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28548889 PubMed]
 
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
Line 25: Line 21:
  
 
[[Category:Breast cancer medications]]
 
[[Category:Breast cancer medications]]
−
[[Category:Non-small cell lung cancer medications]]
 
  
 
[[Category:FDA approved in 2020]]
 
[[Category:FDA approved in 2020]]

Revision as of 00:02, 25 April 2020

Mechanism of action

From the NCI Drug Dictionary: An antibody-drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis.

Diseases for which it is used

History of changes in FDA indication

  • 4/22/2020: Granted accelerated approval for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease.

Also known as

  • Code names: IMMU-132, RS7-SN38
  • Generic name: sacituzumab govitecan-hziy
  • Brand name: Trodelvy
Retrieved from "https://hemonc.org/w/index.php?title=Sacituzumab_govitecan_(Trodelvy)&oldid=44896"